Detalhe da pesquisa
1.
ABO blood group does not influence Child-Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts.
Liver Int
; 42(6): 1386-1400, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35025128
2.
Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France.
Dig Dis Sci
; 66(3): 881-898, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32303953
3.
Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status.
J Hepatol
; 73(6): 1434-1445, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32615276
4.
Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy.
Gastroenterology
; 156(4): 997-1009.e5, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30768988
5.
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.
Liver Int
; 40(8): 1841-1852, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32449966
6.
Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
Gastroenterology
; 155(5): 1436-1450.e6, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30031138
7.
Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.
Gastroenterology
; 155(2): 431-442.e10, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29729258
8.
Non-virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohort.
J Viral Hepat
; 26(3): 384-396, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30380181
9.
Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication.
Hepatology
; 68(4): 1245-1259, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29663511
10.
Hepatitis C virus infection impacts work productivity and fatigue: An epidemiologic real-life study.
Ann Hepatol
; 18(5): 708-714, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31164266
11.
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.
Gastroenterology
; 152(1): 142-156.e2, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27641509
12.
Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients.
Am Heart J
; 198: 4-17, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29653647
13.
Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort).
Gut
; 66(2): 330-341, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26511797
14.
Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients.
Hepatology
; 74(4): 2304-2306, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34008214
15.
Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir).
Hepatology
; 64(4): 1136-47, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27348075
16.
Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort).
Hepatology
; 62(3): 737-50, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25678021
17.
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France.
Dig Dis Sci
; 61(10): 3072-3083, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26821154
18.
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.
Ann Hepatol
; 15(3): 333-49, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27049487
19.
STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.
J Hepatol
; 62(6): 1246-55, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25559324
20.
A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin.
Liver Int
; 34(10): 1550-9, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24329937